110 patents
Page 3 of 6
Utility
Immunomodulatory IL-2 agents in combination with immune checkpoint inhibitors
15 Feb 22
The invention provides compositions and methods of treating cancer in a patient with a combination therapy comprising a fusion protein of SEQ ID NO: 1 in combination with an immune checkpoint inhibitor.
Heather C. Losey, Jared Lopes, Raymond J. Winquist
Filed: 16 Oct 20
Utility
Compositions and methods for subcutaneous administration of cancer immunotherapy
15 Feb 22
The invention provides compositions, methods and treatment regimens for treating cancer comprising periodic subcutaneous administration of the fusion protein of SEQ ID NO:1 to a cancer patient resulting in enhanced activation of CD8+ T-cells with minimal effects on regulatory T cell (Treg) expansion and providing enhanced anti-tumor efficacy while also mitigating T cell inactivation/exhaustion.
Heather C. Losey, Jared Lopes, Lei Sun, Raymond J. Winquist
Filed: 10 Jun 20
Utility
Composition for treating mental illness
8 Feb 22
The present invention relates to the discovery of a novel opioid modulator effective in reducing pharmacologically induced weight gain associated with atypical antipsychotic use.
Daniel R. Deaver, Mark Todtenkopf
Filed: 15 Oct 20
Utility
Compounds for the Treatment of Pain
3 Feb 22
Provided herein are compounds that are useful in the treatment of pain in a subject.
Thomas Andrew Wynn, Juan C. Alvarez, Demetri Theodore Moustakas, Markus Haeberlein, Lewis D. Pennington
Filed: 12 Oct 21
Utility
Prodrugs of fumarates and their use in treating various diseases
25 Jan 22
Tarek A. Zeidan, Scott Duncan, Christopher P. Hencken, Thomas Andrew Wynn, Carlos N. Sanrame
Filed: 7 Aug 20
Utility
Substituted pyridines as inhibitors of histone deacetylase
18 Jan 22
Provided herein are compounds and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of conditions associated with inhibition of HDAC (e.g., HDAC2).
Nathan Oliver Fuller, John A. Lowe, III
Filed: 7 Aug 18
Utility
Bicyclic inhibitors of histone deacetylase
18 Jan 22
Provided herein are compounds and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of conditions associated with inhibition of HDAC (e.g., HDAC2).
Nathan Oliver Fuller, John A. Lowe, III
Filed: 31 Aug 20
Utility
Prodrugs of secondary amine compounds
18 Jan 22
Laura Cook Blumberg, John A. Lowe, III, Orn Almarsson, Juan C. Alvarez, Tarek A. Zeidan
Filed: 6 Sep 19
Utility
IL-2 Fusion Polypeptide Compositions and Methods of Making and Using the Same
23 Dec 21
Provided herein are compositions comprising polypeptides comprising a circularly permuted interleukin-2 (IL-2) fused to the extracellular portion of an IL-2Rα chain, and methods of making and using such compositions.
Francisca O. Gbormittah, Tarek A. Zeidan
Filed: 10 May 21
Utility
IL-2 Fusion Polypeptide Compositions and Methods of Making and Using the Same
2 Dec 21
Provided herein are compositions comprising polypeptides comprising a circularly permuted interleukin-2 (IL-2) fused to the extracellular portion of an IL-2Rα chain, and methods of making and using such compositions.
Francisca O. Gbormittah, Tarek A. Zeidan, Mayur Kalariya
Filed: 10 May 21
Utility
Methods for treating antipsychotic-induced weight gain
30 Nov 21
The present invention relates to the discovery of a novel opioid modulator effective in reducing pharmacologically induced weight gain associated with atypical antipsychotic use.
Daniel R. Deaver, Mark Todtenkopf
Filed: 12 Jun 20
Utility
Compounds for the treatment of pain
23 Nov 21
Provided herein are compounds that are useful in the treatment of pain in a subject.
Thomas Andrew Wynn, Juan C. Alvarez, Demetri Theodore Moustakas, Markus Haeberlein, Lewis D. Pennington
Filed: 13 Feb 20
Utility
Immunostimulatory Agents In Combination with Angiogenesis Inhibitors
11 Nov 21
The invention provides compositions and methods of treating cancer in a patient with a combination therapy comprising administering to the patient a fusion protein of SEQ ID NO: 1, in combination with an angiogenesis inhibitor (e.g., an anti-VEGF antibody or lenvatinib).
Jared Lopes, Heather C. Losey, Raymond J. Winquist
Filed: 15 Apr 21
Utility
Immunostimulatory Agents In Combination with Angiogenesis Inhibitors
4 Nov 21
The invention provides compositions and methods of treating cancer in a patient with a combination therapy comprising administering to the patient a fusion protein of SEQ ID NO: 1, in combination with an angiogenesis inhibitor.
Jared Lopes, Heather C. Losey, Raymond J. Winquist, Rachel Dusek, Andrew David Simmons
Filed: 15 Apr 21
Utility
Aripiprazole prodrug composition
26 Oct 21
Described is a composition comprising (a) a population of particles of an aripiprazole prodrug having a volume based particle size (Dv50) of less than 1000 nm and (b) at least one surface stabilizer comprising an adsorbed component which is adsorbed on the surface of the aripiprazole prodrug particles and a free component available for solubilisation of the aripiprazole prodrug.
Philip Cresswell, Magali Hickey, Kristopher Perkin, Greg Smith, Elaine Liversidge, Brian Steinberg, David Manser, Tarek Zeidan
Filed: 17 Jun 20
Utility
Sustained Release Aminopyridine Composition
7 Oct 21
A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.
Sean Cunningham, Seamus Mulligan, Michael Myers
Filed: 21 Jun 21
Utility
Bicyclic Inhibitors of Histone Deacetylase
9 Sep 21
Nathan Oliver Fuller, John A. Lowe, III
Filed: 12 Jul 19
Utility
Hetero-halo Inhibitors of Histone Deacetylase
9 Sep 21
This invention provides compounds that are inhibitors of HDAC2.
Martin R. Jefson, John A. Lowe, III, Fabian Dey, Andreas Bergmann, Andreas Schoop, Nathan Oliver Fuller
Filed: 28 Dec 20
Utility
Inhibitors of Histone Deacetylase
9 Sep 21
Nathan Oliver Fuller, John A. Lowe, III
Filed: 12 Jul 19
Utility
Pharmaceutical compositions having improved storage stability
24 Aug 21
The present invention relates to a pharmaceutical composition that provides long-term stability of a hydrolytically labile antipsychotic agent
Jason M. Perry, Daniel R. Deaver, Magali B. Hickey, Julius F. Remenar, Jennifer Vandiver, Michael J. Palmieri, Jr., Zhengzheng Pan
Filed: 30 Mar 20